The Association Between Poor Antiretroviral Adherence and Unsafe Sex: Differences by Gender and Sexual Orientation and Implications for Scale-up of Treatment as Prevention

AIDS and Behavior

Volumn 18, Issue 8, 2014, Pages 1541-1547

  Remien, Robert H ^a   Dolezal, Curtis ^a   Wagner, Glenn J ^b   Goggin, Kathy ^c   Wilson, Ira B ^d   Gross, Robert ^e   Rosen, Marc I ^f   Shen, Jie ^g   Simoni, Jane M ^h   Golin, Carol E ⁱ   Arnsten, Julia H ^j   Bangsberg, David R ^k   Liu, Honghu ^g  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b RAND CORPORATION   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^d BROWN UNIVERSITY   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ IL   (United States)

^j ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^k MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

ART adherence; Depression; Sexual risk behavior; Substance use; Test and treat

Indexed keywords

ADULT; ATTITUDE TO HEALTH; BISEXUALITY; CLINICAL TRIAL; COMPLICATION; DEPRESSION; DIRECTIVE COUNSELING; FEMALE; HETEROSEXUALITY; HIV INFECTIONS; HUMAN; MALE; MALE HOMOSEXUALITY; MEDICATION COMPLIANCE; MULTICENTER STUDY; PSYCHOLOGY; RISK FACTOR; SEXUAL BEHAVIOR; SEXUALITY; TRANSMISSION; UNITED STATES; UNSAFE SEX;

ADULT; BISEXUALITY; DEPRESSION; DIRECTIVE COUNSELING; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HETEROSEXUALITY; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; MEDICATION ADHERENCE; RISK FACTORS; SEXUAL BEHAVIOR; SEXUAL PARTNERS; UNITED STATES; UNSAFE SEX;

EID: 84886979340     PISSN: 10907165     EISSN: 15733254     Source Type: Journal    
DOI: 10.1007/s10461-013-0656-0     Document Type: Article

References (43)

1. Folkers GK, Fauci AS. Controlling and ultimately ending the HIV/AIDS pandemic: a feasible goal. JAMA. 2010;304:350–1.
2. Panel on Antiretroviral Guidelines for Adults and Adolescents (2011) Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 24 Feb 2011.
3. The HIV-CAUSAL Collaboration. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS. 2010;24:123–37.
4. Fisher JD, Smith LR, Lenz EM. Secondary prevention of HIV in the United States: past, current, and future perspectives. J Acquir Immune Defic Syndr. 2010;55(Suppl 2):S106–15.
5. Remien RH, Mellins CA. Long-term psychosocial challenges for people living with HIV: let’s not forget the individual in our global response to the pandemic. AIDS. 2007;21(Suppl 5):S55–63.
6. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15:1181–3.
7. Wood E, Hogg RS, Yip B, Harrigan PR, O’Shaughnessy MV, Montaner JS. Effect of medication adherence on survival of HIV infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 × 10(9) cells/L. Ann Intern Med. 2003;139:810–6.
8. Kitahata MM, Reed SD, Dillingham PW, et al. Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death. Int J STD AIDS. 2004;15:803–10.
9. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002;34:1115–21.
10. Wood E, Hogg RS, Yip B, Harrigan PR, O’Shaughnessy MV, Montaner JS. The impact of adherence on CD4 cell count responses among HIV-infected patients. J Acquir Immune Defic Syndr. 2004;35:261–8.
11. Blower SM, Aschenbach AN, Kahn JO. Predicting the transmission of drug-resistant HIV: comparing theory with data. Lancet Infect Dis. 2003;3:10–1.
12. Grant RM, Hecht FM, Warmerdam M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA. 2002;288:181–8.
13. Granich RM, Gilks CF, Dye C, DeCock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48–57.
14. Walensky RP, Paltiel AD, Losina E, et al. Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis. 2010;51(4):392–400.
15. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505.
16. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med. 2000;342:921–9.
17. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52:793–800.
18. CDC. Vital signs: HIV prevention through care and treatment. MMWR CDC Surveill Summ. 2011;60(47):1618–23.
19. Kashuba AD, Dyer JR, Kramer LM, et al. Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1999;43:1817–26.
20. Wilson TE, Barron Y, Cohen M, et al. Adherence to antirertroviral therapy and its association with sexual behavior in a national sample of women with human immunodeficiency virus. Clin Infect Dis. 2002;34:529–34.
21. Kalichman SC, Rompa D. Treatment adherence and unprotected sex practices among persons receiving antiretroviral therapy. Sex Transm Infect. 2003;79:59–61.
22. Kalichman SC, Cherry C, Amaral CM, et al. Adherence to antiretroviral therapy and HIV transmission risks: implications for test-and-treat approaches to HIV prevention. AIDS Patient Care STDS. 2010;24(5):271–7.
23. Friedman MS, Marshal MP, Stall R, et al. Associations between substance use, sexual risk taking and HIV treatment adherence among homeless people living with HIV. AIDS Care. 2009;21(6):692–700.
24. Remien RH, Exner TM, Morin SF, et al. Medication adherence and sexual risk behavior among HIV-infected adults: implications for transmission of resistant virus. AIDS Behav. 2007;11(5):663–75.
25. Buscher A, Hartman C, Kallen M, Giordano T. Validity of self-report measures in assessing antiretroviral adherence of newly diagnosed, HAART-naïve HIV patients. HIV Clin Trials. 2011;12(5):244–54.
26. Thirumurthy H, Siripong N, Vreeman R, et al. Differences between self-reported and electronically monitored adherence among patients receiving antiretroviral therapy in a resource-limited setting. AIDS. 2012;26(18):2399–403.
27. Nakimuli-Mpungu E, Mojtabai R, Alexandre PK, et al. Lifetime depressive disorders and adherence to anti-retroviral therapy in HIV-infected Ugandan adults: a case–control study. J Affect Disord. 2013;145(2):221–6.
28. Rosen MI, Black AC, Arnsten JH, et al. Association between use of specific drugs and adherence: findings from MACH14. AIDS Behav. 2013;17(1):142–7.
29. Mimiaga M, Reisner S, Fontaine Y, et al. Walking the line: stimulant use during sex and HIV risk behavior among Black urban MSM. Drug Alcohol Depend. 2010;110(1–2):30–7.
30. Kuo I, Greenberg A, Magnus M, et al. High prevalence of substance use among heterosexuals living in communities with high rates of AIDS and poverty in Washington, DC. Drug Alcohol Depend. 2011;117(2–3):139–44.
31. Lennon CA, Huedo-Medina TB, Gerwien DP, et al. A role for depression in sexual risk reduction for women? A meta-analysis of HIV prevention trials with depression outcomes. Soc Sci Med. 2012;75(4):688–98.
32. Liu H, Wilson IB, Goggin K, et al. MACH14: a multi-site collaboration on ART adherence among 14 institutions. AIDS Behav. 2013;17(1):127–41.
33. Wagner GJ, Goggin K, Remien RH, et al. A closer look at depression and its relationship to HIV antiretroviral adherence. Ann Behav Med. 2011;42:352–60.
34. Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck depression inventory: twenty-five years of evaluation. Clin Psychol Rev. 1988;8:77–100.
35. Radloff LS. The CES-D scale: a self report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385–401.
36. Zaller ND, Fu JJ, Nunn A, Beckwith CG. Linkage to care for HIV-infected heterosexual men in the United States. Clin Infect Dis. 2011;52(Suppl 2):S223–30.
37. Courtenay WH. Constructions of masculinity and their influence on men’s well-being: a theory of gender and health. Soc Sci Med. 2000;50(10):1385–401.
38. Baggaley RF, White RG, Boily MC. HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol. 2010;39:1048–63.
39. Kalichman SC, Cherry C, White D, et al. Sexual HIV transmission and antiretroviral therapy: a prospective cohort study of behavioral risk factors among men and women living with HIV/AIDS. Ann Behav Med. 2011;42:111–9.
40. Kennedy CE, Medley AM, Sweat MD, O’Reilly KR. Behavioral intervention for HIV positive prevention in developing countries: a systematic review and meta-analysis. Bull World Health Organ. 2010;88(8):615–23.
41. Scott-Sheldon LA, Huedo-Medina TB, Warren MR, Johnson BT, Carey MP. Efficacy of behavioral interventions to increase condom use and reduce sexually transmitted infections: a meta-analysis, 1991 to 2010. J Acquir Immune Defic Syndr. 2011;58(5):489–98.
42. Simoni JM, Pearson CR, Pantalone DW, Marks G, Crepaz N. Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-analytic review of randomized controlled trials. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S23–35.
43. El-Bassel N, Gilbert L, Witte S, Wu E, Hunt T, Remien RH. Couple-based HIV prevention in the United States: advantages, gaps, and future directions. J Acquir Immune Defic Syndr. 2010;55(Suppl 2):S98–101.